SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis

Conclusions
SARS-COV-2 omicron breakthrough infections are more prevalent in patients with MS on anti-CD20 therapies and S1PR modulators compared with other patients with MS, which correlated with decreased humoral responses after vaccination. Humoral responses after infection were higher in S1PR modulator-treated patients in comparison to patients on anti-CD20 therapies, suggesting that immunological protection from contracting infection or repeated exposures may differ between these therapies.

Source: Journal of Neurology, Neurosurgery and Psychiatry - March 14, 2023 Category: Neurosurgery Authors: van Kempen, Z. L. E., Stalman, E. W., Steenhuis, M., Kummer, L. Y. L., van Dam, K. P. J., Wilbrink, M. F., ten Brinke, A., van Ham, S. M., Kuijpers, T., Rispens, T., Eftimov, F., Wieske, L., Killestein, J., on behalf of the T2B! immunity against SARS-CoV- Tags: Multiple sclerosis Source Type: research